Skip to content
value.today

AvroBio, Inc.

Total raised
$68 M
2 rounds on record
Latest round
$61 M
Jan 2018
First round on record
Jul 2016
Today
Went public
See the company page

AvroBio, Inc. is listed today as Tectonic Therapeutic, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AvroBio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$185 MPrivate placement after listing$50 to $250 million

AvroBio, Inc.: Private sale, Feb 2025

Investors in this round

29 investors had bought by the notice of Feb 14, 2025: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for AvroBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$185 M of $185 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$11,101,659
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alise Reicin · Executive Officer, Director
  • Daniel Lochner · Executive Officer
  • Marc K. Schwabish · Executive Officer
  • Marcella K. Ruddy · Executive Officer
  • Peter McNamara · Executive Officer
  • Phillip B. Donenberg · Director
  • Praveen P. Tipirneni · Director
  • Stefan P. Vitorovic · Director
  • Terrance K. McGuire · Director
  • Timothy K. Springer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Sandler & Co. (CRD 665) · New York, New YorkSold in all US states
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • TD Securities (USA) LLC (CRD 18476) · New York, New YorkSold in all US states
  • Wells Fargo Securities, LLC (CRD 126292) · New York, New YorkSold in all US states

Signed by Alise Reicin, Ceo. Source: SEC Form D, newest notice filed Feb 14, 2025. Read the notice at the SEC.

equitySEC
Jan 2018$61 MNo. 2$50 to $250 million

AvroBio, Inc.: Raise no. 2, Jan 2018

Investors in this round

15 investors had bought by the notice of Feb 2, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for AvroBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$61 M of $61 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Mason · Executive Officer
  • Deanna Petersen · Executive Officer
  • Geoffrey MacKay · Executive Officer, Director
  • Katina Dorton · Executive Officer
  • Kim Warren · Executive Officer
  • Bruce Booth · Director
  • Christopher Paige · Director
  • Ian Clark · Director
  • Joshua Resnick · Director
  • Scott Requadt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold shown in item 13 and number of investors shown in item 14 include $2,508,797 from 2 non-US investors.”

Signed by Geoffrey MacKay, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 2, 2018. Read the notice at the SEC.

equitySEC
Jul 2016$8 MNo. 1$2 to $10 million

AvroBio, Inc.: Raise no. 1, Jul 2016

Investors in this round

3 investors had bought by the notice of Aug 3, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for AvroBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $25 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Mason · Executive Officer
  • Deanna Petersen · Executive Officer
  • Geoffrey MacKay · Executive Officer, Director
  • Kim Warren · Executive Officer
  • Bruce Booth · Director
  • Christopher Paige · Director
  • Joshua Resnick · Director
  • Scott Requadt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey MacKay, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 3, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AvroBio, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).

    SEC Form D · Feb 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2025

That is all the official record says: AvroBio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of AvroBio, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in AvroBio, Inc.
InvestorKindAmountRoundRoleSource
Atlas Venture Associates X, LLCVenture capitalnot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Atlas Venture Associates X, L.P.Venture capitalnot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Atlas Venture Fund X, L.P.Venture capitalnot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Clarus Lifesciences III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Clarus Ventures III GP, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Clarus Ventures III, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund VI (GP), L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund VI, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund VI Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Svlsf VI, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Largest shareholders today

Institutions holding Tectonic Therapeutic, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AvroBio, Inc.
NameRoleNamed in
Alise ReicinExecutive officerFeb 2025
Daniel LochnerExecutive officerFeb 2025
Marc K. SchwabishExecutive officerFeb 2025
Marcella K. RuddyExecutive officerFeb 2025
Peter McNamaraExecutive officerFeb 2025
Christopher MasonExecutive officerFeb 2018
Deanna PetersenExecutive officerFeb 2018
Geoffrey MacKayExecutive officerFeb 2018
Katina DortonExecutive officerFeb 2018
Kim WarrenExecutive officerFeb 2018
Alise ReicinDirectorFeb 2025
Phillip B. DonenbergDirectorFeb 2025
Praveen P. TipirneniDirectorFeb 2025
Stefan P. VitorovicDirectorFeb 2025
Terrance K. McGuireDirectorFeb 2025
Timothy K. SpringerDirectorFeb 2025
Bruce BoothDirectorFeb 2018
Christopher PaigeDirectorFeb 2018
Geoffrey MacKayDirectorFeb 2018
Ian ClarkDirectorFeb 2018
Joshua ResnickDirectorFeb 2018
Scott RequadtDirectorFeb 2018

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.